- Home
- CRGX vs ICG Comparison
CRGX vs ICG Comparison
Compare CRGX & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ICG
- Stock Information
- Founded
- CRGX 2021
- ICG 2017
- Country
- CRGX United States
- ICG China
- Employees
- CRGX N/A
- ICG N/A
- Industry
- CRGX
- ICG Semiconductors
- Sector
- CRGX
- ICG Technology
- Exchange
- CRGX Nasdaq
- ICG Nasdaq
- Market Cap
- CRGX 213.5M
- ICG 230.3M
- IPO Year
- CRGX 2023
- ICG 2023
- Fundamental
- Price
- CRGX $4.02
- ICG $2.32
- Analyst Decision
- CRGX Hold
- ICG Strong Buy
- Analyst Count
- CRGX 7
- ICG 2
- Target Price
- CRGX $4.67
- ICG $9.50
- AVG Volume (30 Days)
- CRGX 763.5K
- ICG 24.0K
- Earning Date
- CRGX 05-16-2025
- ICG 05-19-2025
- Dividend Yield
- CRGX N/A
- ICG N/A
- EPS Growth
- CRGX N/A
- ICG N/A
- EPS
- CRGX N/A
- ICG 0.12
- Revenue
- CRGX N/A
- ICG $38,602,978.00
- Revenue This Year
- CRGX $58.18
- ICG N/A
- Revenue Next Year
- CRGX N/A
- ICG $147.04
- P/E Ratio
- CRGX N/A
- ICG $20.74
- Revenue Growth
- CRGX N/A
- ICG 242.68
- 52 Week Low
- CRGX $3.00
- ICG $1.40
- 52 Week High
- CRGX $25.45
- ICG $12.04
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- ICG 52.60
- Support Level
- CRGX $3.97
- ICG $2.01
- Resistance Level
- CRGX $4.66
- ICG $2.56
- Average True Range (ATR)
- CRGX 0.20
- ICG 0.21
- MACD
- CRGX -0.05
- ICG 0.12
- Stochastic Oscillator
- CRGX 6.25
- ICG 78.32
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.